127 related articles for article (PubMed ID: 27574017)
1. The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7.
Liu ZG; Tang J; Chen Z; Zhang H; Wang H; Yang J; Zhang H
Int J Oncol; 2016 Sep; 49(3):1039-45. PubMed ID: 27574017
[TBL] [Abstract][Full Text] [Related]
2. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.
Hayman TJ; Wahba A; Rath BH; Bae H; Kramp T; Shankavaram UT; Camphausen K; Tofilon PJ
Clin Cancer Res; 2014 Jan; 20(1):110-9. PubMed ID: 24198241
[TBL] [Abstract][Full Text] [Related]
3. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
4. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
[TBL] [Abstract][Full Text] [Related]
5. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
7. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
8. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
Zhang H; Dou J; Yu Y; Zhao Y; Fan Y; Cheng J; Xu X; Liu W; Guan S; Chen Z; shi Y; Patel R; Vasudevan SA; Zage PE; Zhang H; Nuchtern JG; Kim ES; Fu S; Yang J
Apoptosis; 2015 Jan; 20(1):50-62. PubMed ID: 25425103
[TBL] [Abstract][Full Text] [Related]
9. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
[TBL] [Abstract][Full Text] [Related]
10. The mTOR Kinase Inhibitor INK128 Blunts Migration of Cultured Retinal Pigment Epithelial Cells.
Calton MA; Vollrath D
Adv Exp Med Biol; 2016; 854():709-15. PubMed ID: 26427479
[TBL] [Abstract][Full Text] [Related]
11. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
[TBL] [Abstract][Full Text] [Related]
12. The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.
Lou HZ; Weng XC; Pan HM; Pan Q; Sun P; Liu LL; Chen B
Biochem Biophys Res Commun; 2014 Jul; 450(2):973-8. PubMed ID: 24971544
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.
Jiang SJ; Wang S
Tumour Biol; 2015 Sep; 36(10):8177-84. PubMed ID: 25990456
[TBL] [Abstract][Full Text] [Related]
14. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
15. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
16. The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells.
Pan H; Xu LH; Ouyang DY; Wang Y; Zha QB; Hou XF; He XH
Inflammation; 2014 Jun; 37(3):756-65. PubMed ID: 24385238
[TBL] [Abstract][Full Text] [Related]
17. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum stress sensitizes human esophageal cancer cell to radiation.
Pang XL; He G; Liu YB; Wang Y; Zhang B
World J Gastroenterol; 2013 Mar; 19(11):1736-48. PubMed ID: 23555162
[TBL] [Abstract][Full Text] [Related]
19. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor INK128 attenuates dextran sodium sulfate-induced colitis by promotion of MDSCs on Treg cell expansion.
Shi G; Li D; Ren J; Li X; Wang T; Dou H; Hou Y
J Cell Physiol; 2019 Feb; 234(2):1618-1629. PubMed ID: 30132862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
